afternoon. recent of for Jordyn, thank and everyone as joining earnings call I'm quarterly you, you us appointment be since joining you the company. Thank CEO my the this delighted on to first
believer a that strategy way micropeptides CohBar's development therapeutic the the am potential has the Before lead main encoded multiple could you and I the of I to to that wanted in that the I treat we the firm DNA provide join introduce are products the mitochondrial revolutionize to because business, of patients. decided an about update a I to tell CohBar? to myself team. minutes CohBar Why few on simply take reasons identifying Quite
is mitochondrial ensuring underappreciated a potentially the those throughout is of encoded founders is and process play CohBar's role related drug know narrow ignored beyond companies relatively the roles What proving extend and our important to you function be CohBar, key believed DNA has essential energy that the mitochondrial until body. to significant energy just to and mitochondria time, production. since in DNA. been nuclear normal As mining have But have and roles point. many that primarily spent and company the to the limited historically mitochondria functions processes peptides by money appreciated out This largely was of
we mitochondria, is derived function. peptides, CohBar Instead, to developing we may little mitochondrial by Although focused these originate thought are as biology relation have just in on or many with aspects the on traditionally targeting which impacted that that what we changes diseases mitochondrial mitochondrial disease. of are are of in focusing no not impact peptides of
I think peptide analogy pancreatic a a useful produced is by insulin, cells.
particular normal Although this is the disease regulation typically peptide as the the roles of a don't by follow same in critical in impacts organ the function that believe peptides condition pathways. abnormalities pancreas, that many normal results We imbalance insulin that important we biological multiple such Rather, rather pancreas. basic the or the mitochondria is that in These insulin function primarily systemic many as maintaining the sensitivity even pancreas. insulin conditions a a a think other level peptides originate of significant organ than systems pattern in involve in produced of of play to production though pancreas.
could the a changes worsen As certain of or result, to lead in levels these exacerbating physiological plasma responses, diseases. resulting peptides in or adopted now
normal our may peptides restore in are may impact CXCRX homeostasis, we program. program they these as goal the CBXXXX pathways or overregulated in our signaling oncology block pathways to example, regulatory setting For
they both cases, mechanisms. many may work in through fact In
potential Additionally, therapeutics process. slow as the peptides even to be studies certain suggest or mitochondrial reverse certain of aging may to have the aspects used
a team has could IP are being areas Given a able many approach. XX across that XXX, issued over more range believe been peptides large of by that diseases from the and number XX carve mitochondrial identified the that benefit derived wide than of filings. attractive therapeutic we potentially different first patent an patents to CohBar mover there the space, in position this has with out CohBar Further CohBar
roles have been familiarity partnering uniformly a potential, me a them track bring quality I that And also this relative hard-working will treatment developing on the novel employees peptides and process an their drugs, have the dedicated the that for companies. I these possibly relevant including occurring to with of record of AIDS. on diseases Additionally, impact profile existing decision-making public is early into drew Barzilai, and joining will since promise and advisers. who the I to CohBar the impressed to company leadership skills a the as both potential today. attracted only reducing undertake to the impressed couple of aging the development. passion for also power was private exploring the form HIV of has and licensing real mitochondria-based and I've success a for the experience on of by of also the although basis process the itself a arrangements been treatment into first-hand that world-class naturally are Jeff and negotiating practicing and career the physicians have that development the how the physician scientists importantly, by ultimately when believe achieve weeks, wide important risk. worked including remarkable the from in mitochondrial for whether novel significantly Drs. safety the treat paradigms. extensive and It including improved the fit focused Jordyn therapeutics as completely that ground peptides, call expect analogs my me setting, founders variety to and of its Ken, to I of on experience I I've CohBar therapeutic business evaluating team and clinical unlock help insights the whose genome that company we the focusing and And at company. is agents Cohen started of Having company complex in I
paper deal putting been critical on which agreements, in in beyond productive have implementing the a is actually Additionally, I living transforming deals place, relationship. long-term into and for responsible with those a
I opportunities, a long-term any continues various align partners way CohBar's help that in that As and we will to sure right up set pipeline that will develop we incentives partnering make the believe partner or and us select partnership maximize success. expertise evaluate and
appropriately that I million prior the provide like strategic first million moving related raising forward. the been will That in Finally, with at be that the I'd financing in as from quarter. of remainder investments while key approximately is issuances we corporate approximately companies, partners ensure equity have equity background, $XX to work transactions. experience including funded involved in invaluable With during now developments CohBar overview an to to $XXX
in enrollment study and last clinical most perhaps we patient Xb Phase importantly, ongoing and CBXXXX obesity. NASH First completed for our of of the
last Additionally, their completed announced visit. last that subject had final we month the
study in early As trial remains from we and July. the on track planning a result, line the data are to top release
respiratory now Second, we new idiopathic next of announced CBXXXX-X selection to initiated as product an fibrosis Acute associated for pulmonary the other with enable ARDS potential have the with finally, National distress clinical or Institute announced we fibrotic The our promising NIAID to of Diseases and potential the ARDS. in treatment and of with the this or work analogs conduct preclinical analogs IND-enabling studies Allergy validated of the relationship team and candidate NIAID for be his treatment CBXXXX of COVID-XX-associated exciting models the IPF of evaluate diseases. And new tested candidate. Ken syndrome will our COVID-XX. or relationship Infectious to the for
of my wide a a in pipeline mitochondria-based As join a therapeutic to current this. I appeal CohBar that mentioned review confirms promise of impact therapeutics decision and to part our the related earlier, large different areas the range could of
on NASH, these the Scientific we to trials. some the Since will Cundy said our our tip We programs lead of now including our just our have on peptides confine the multiple five obesity details in to are and programs over current are to call current and our the I'd our like is XXX which has turn pipeline further team remarks of Officer, Ken of disease areas. ways ongoing efforts in over programs, targeting programs. focusing CBXXXX those Having fibrosis many we identified different that, technical the Ken? to more iceberg. highlight Chief
